Olfactory Function in Patients With Sinonasal Diseases: A Multicenter Observational Study
Olfactory Profile of Patients With Sinonasal Diseases: A Multicenter Cross-Sectional Observational Study in Brazil
This multicenter, cross-sectional observational study aims to characterize olfactory function in patients with sinonasal diseases and investigate its associations with disease severity, clinical characteristics, and inflammatory markers. Olfactory function will be assessed using the MultiScent-20 digital odor identification test. Additional assessments will include sinonasal symptom severity, quality of life, endoscopic and radiological findings, and clinical and laboratory markers suggestive of type 2 inflammation. Healthy volunteers without olfactory complaints will serve as a comparison group. The study is expected to enroll 3,800 participants across participating centers in Brazil.
Studieoversigt
Status
Status
Betingelser
Betingelser
Detaljeret beskrivelse
This is a multicenter, cross-sectional observational study conducted in Brazilian outpatient otolaryngology settings. The study aims to investigate olfactory function in patients with chronic rhinosinusitis and other sinonasal diseases and to explore its associations with clinical manifestations, disease severity, and inflammatory characteristics.
Olfactory function will be objectively assessed using the MultiScent-20 digital odor identification test, which provides a score ranging from 0 to 20, with higher scores indicating better olfactory performance. Participants will undergo a single study assessment.
Clinical data will include sinonasal symptoms, SNOT-22 scores, visual analog scale ratings, nasal polyp scores, previous sinonasal surgeries, relevant comorbidities, and alcohol intolerance. Laboratory, histopathological, and imaging findings obtained during routine clinical care within the predefined eligibility window will be collected when available.
Criteria suggestive of type 2 inflammation will be evaluated using predefined clinical and laboratory characteristics. Missing clinical or laboratory information will not constitute an exclusion criterion. Analyses involving individual variables will include participants with the corresponding available data, whereas the total count of type 2 inflammatory criteria will be calculated only when all eight criteria have been assessed.
A comparison group of healthy volunteers without olfactory complaints will also be included. No therapeutic intervention will be administered as part of this observational study.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Gustavo Subtil M. Freire, MSc
- Telefonnummer: +55 61 2028-5000
- E-mail: gustavo.freire@ebserh.gov.br
Studiesteder
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasilien
- Rekruttering
- Hospital Universitário Professor Edgard Santos (HUPES)
-
-
Federal District
-
Brasília, Federal District, Brasilien
- Rekruttering
- Hospital Universitário de Brasília (HUB)
-
-
Goiás
-
Goiânia, Goiás, Brasilien
- Rekruttering
- Hospital das Clínicas da UFG
-
-
Paraná
-
Curitiba, Paraná, Brasilien
- Rekruttering
- Hospital IPO - sede Água Verde
-
-
Pernambuco
-
Recife, Pernambuco, Brasilien
- Rekruttering
- Hospital das Clínicas da UFPE
-
-
Piauí
-
Teresina, Piauí, Brasilien
- Rekruttering
- Hospital Getúlio Vargas (HGV)
-
-
Rio Grande do Sul
-
Canoas, Rio Grande do Sul, Brasilien
- Rekruttering
- Hospital Universitário Canoas
-
Porto Alegre, Rio Grande do Sul, Brasilien
- Rekruttering
- Hospital de Clínicas de Porto Alegre (HCPA)
-
-
Rio de Janeiro
-
Rio de Janeiro, Rio de Janeiro, Brasilien
- Rekruttering
- Hospital Universitário Pedro Ernesto
-
-
São Paulo
-
Ribeirão Preto, São Paulo, Brasilien
- Rekruttering
- Hospital das Clínicas da FMRP-USP - Campus
-
São Paulo, São Paulo, Brasilien
- Rekruttering
- Hospital das Clínicas da FMUSP
-
São Paulo, São Paulo, Brasilien
- Rekruttering
- Hospital São Paulo - Hospital Universitário da UNIFESP
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Adults aged 18 years or older with chronic rhinosinusitis or other sinonasal diseases and healthy volunteers without olfactory complaints, recruited at participating outpatient centers in Brazil.
Beskrivelse
Inclusion Criteria:
Adults aged 18 years or older. Patients with chronic rhinosinusitis or other sinonasal diseases, or healthy volunteers without olfactory complaints participating in the comparison group.
Ability to understand and complete the study assessments.
Exclusion Criteria:
Illiteracy. Respiratory tract infection within the preceding seven days. Sinonasal surgery within the preceding six months. History of severe head trauma. Diagnosis of a neurodegenerative disease.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: OTHER
- Tidsperspektiver: CROSS_SECTIONAL
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
|---|
|
Sinonasal Disease Participants
Adults with chronic rhinosinusitis or other sinonasal diseases. |
|
Healthy Comparison Participants
Healthy adults without olfactory complaints. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
MultiScent-20 odor identification score
Tidsramme: Once at enrollment (cross-sectional assessment).
|
Total number of correctly identified odors on the 20-item MultiScent-20 digital odor identification test. Scores range from 0 to 20; higher scores indicate better odor identification performance. |
Once at enrollment (cross-sectional assessment).
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Sinonasal Outcome Test-22 (SNOT-22) total score
Tidsramme: Once at enrollment (cross-sectional assessment).
|
Patient-reported sinonasal symptom burden assessed using the 22-item SNOT-22 questionnaire. Total scores range from 0 to 110; higher scores indicate greater symptom burden. |
Once at enrollment (cross-sectional assessment).
|
|
Severity of four sinonasal symptoms on visual analog scales
Tidsramme: Once at enrollment (cross-sectional assessment).
|
Severity will be assessed separately for nasal obstruction, rhinorrhea, facial pain or pressure, and olfactory dysfunction using four individual visual analog scales (VAS). Each score ranges from 0 (no symptoms) to 10 (maximum symptom intensity). Each symptom score will be analyzed in relation to the MultiScent-20 odor identification score. No combined VAS total score is prespecified. |
Once at enrollment (cross-sectional assessment).
|
|
Nasal Polyp Score (NPS)
Tidsramme: At enrollment, using available routine clinical assessment.
|
Endoscopic nasal polyp burden assessed using the Nasal Polyp Score, ranging from 0 to 8; higher scores indicate greater polyp burden. Applicable to participants with available endoscopic assessment. |
At enrollment, using available routine clinical assessment.
|
|
Lund-Mackay computed tomography score
Tidsramme: At enrollment; CT performed within the 12 months preceding enrollment, if available.
|
Extent of sinonasal opacification on computed tomography evaluated using the Lund-Mackay scoring system (total score 0-24; higher scores indicate more extensive radiologic disease). Assessed when routine-care imaging is available. |
At enrollment; CT performed within the 12 months preceding enrollment, if available.
|
|
Peripheral blood eosinophil count
Tidsramme: At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.
|
Absolute peripheral blood eosinophil count obtained from available routine-care laboratory testing. |
At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.
|
|
Total serum immunoglobulin E (IgE)
Tidsramme: At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.
|
Total serum IgE concentration obtained from available routine-care laboratory testing. |
At enrollment; routine-care laboratory test performed within the 12 months preceding enrollment, if available.
|
|
Number of clinical and laboratory criteria suggestive of type 2 inflammation in chronic rhinosinusitis
Tidsramme: Once at enrollment, using clinical data and available routine-care tests obtained within the preceding 12 months when applicable.
|
Count of predefined clinical and laboratory criteria suggestive of type 2 inflammation in chronic rhinosinusitis, according to the guideline for use of biologics in chronic rhinosinusitis with nasal polyps cited in the study protocol. Clinical criteria: symptom onset between ages 30 and 50 years; marked improvement in olfaction following oral corticosteroid use; adult-onset asthma; aspirin or nonsteroidal anti-inflammatory drug intolerance; and bilateral nasal polyps associated with thick allergic- or eosinophilic-appearing nasal mucus, preferably confirmed by nasal endoscopy. Biomarker criteria: tissue eosinophils ≥10 cells/high-power field; blood eosinophils ≥250 cells/µL; or total serum IgE ≥100 IU/mL. The total number of criteria suggestive of type 2 inflammation will be calculated only for participants with complete data on all eight clinical and laboratory criteria. The count ranges from 0 to 8 and equals the number of positive criteria. |
Once at enrollment, using clinical data and available routine-care tests obtained within the preceding 12 months when applicable.
|
|
Presence of selected comorbidities
Tidsramme: Once at enrollment (cross-sectional assessment).
|
Presence or absence of relevant comorbidities, including asthma and aspirin-exacerbated respiratory disease (AERD), recorded from clinical history. |
Once at enrollment (cross-sectional assessment).
|
|
Number of previous sinonasal surgeries
Tidsramme: Once at enrollment (cross-sectional assessment).
|
The number of previous sinonasal surgeries will be recorded for each participant. |
Once at enrollment (cross-sectional assessment).
|
|
Alcohol intolerance
Tidsramme: Once at enrollment (cross-sectional assessment).
|
Alcohol intolerance will be assessed as a binary variable (yes/no), based on self-reported nasal symptoms following the consumption of alcoholic beverages. |
Once at enrollment (cross-sectional assessment).
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Gustavo Subtil M. Freire, University of Brasilia
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- UNB-OLFATO-RSC-2026
- 68687423.5.0000.5558 (Anden identifikator: Brazilian Research Ethics CAAE)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .